AZN Announces Strategic Equity Investment, Clinical Collaboration with Summit Therapeutics on Cancer Drug
· The NYC Memo
AstraZeneca PLC entered into a strategic equity investment and clinical collaboration agreement with Summit Therapeutics. The collaboration will evaluate sonesitatug vedotin, a Claudin-18.2 ADC, with ivonescimab, a PD-1/VEGF bispecific, in gastrointestinal cancers, and includes plans for broader combinations with AstraZeneca's cancer medicines.